Retatrutide Before FDA Approval? Lilly Just Changed the Conversation
Dave breaks down an unreported Expanded Access Pathway that Eli Lilly has quietly established for Retatrutide.
9 Kesä 20min
Eli Lilly Isn’t Telling Us About Their Future Obesity Drugs
Does Eli Lilly already have the solve for obesity? In this episode of On the Pen — the Weekly Dose Podcast, host Dave Knapp breaks down a stunning comment from Lilly's Chief Scientific Officer Daniel ...
2 Kesä 20min
Retatrutide, Multi Agonist Obesity Drugs, and the PBM Access War
https://linktr.ee/manonthemounjaro
26 Touko 30min
Lilly Bets $8B on Weight Loss Future
https://linktr.ee/manonthemounjaro
19 Touko 23min
The Next Two Weeks in GLP1 Are Huge, Here's Why
http://www.otplinks.com
12 Touko 1h 7min
He Took Retatrutide 40mg and Proved a Point
This episode examines a serious case involving retatrutide, where an individual experienced an overdose due to improper medication administration. We discuss the critical importance of medication safe...
5 Touko 36min
Eli Lilly Earnings Call Recap: Q1 2026
We just got done listening to the quarter one, 2026 Eli Lilly earnings call. There was a lot of information to get into, whether you're interested in retatrutide, eloralintide, or Foundayo, and all of...
30 Huhti 25min
SURVODUTIDE Phase 3 Data: Why Weight Loss Isn't The Whole Story
https://www.otplinks.comA new GLP-1 and glucagon agonist dropped data that was supposed to rival retatrutide, just without the GIP, and on the surface the results look solid. But that is not the real ...
28 Huhti 18min
